The challenge of delivering reliable science and guidelines: Opportunities for all to participate

European Heart Journal

Volumn 35, Issue 36, 2014, Pages 2435-2440a

  Cole, Graham D ^a   Francis, Darrel P ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Clinical governance; Patient safety; Scientific misconduct

Indexed keywords

ACCOUNTABLE CARE ORGANIZATION; ALERTNESS; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; CLINICAL RESEARCH; COMMUNITY ASSESSMENT; DIAGNOSTIC TEST; EMERGENCY CARE; EMPLOYER; FRAUD; HEALTH BELIEF; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH HAZARD; HUMAN; LEADERSHIP; MEDICAL SOCIETY; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OFFENDER; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PEER REVIEW; PERIOPERATIVE PERIOD; PHASE TRANSITION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; RESPONSIBILITY; SCIENCE; TIME TO TREATMENT; INTERPERSONAL COMMUNICATION; MEDICAL RESEARCH; METHODOLOGY; PROFESSIONAL MISCONDUCT; STANDARDS;

BIOMEDICAL RESEARCH; DISCLOSURE; HUMANS; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL MISCONDUCT; RESEARCH DESIGN;

EID: 84907375623     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology (ESC), Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van Den Berghe G, Vermassen F. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009;30:2769-2812.
2. Erasmus Medical Centre. (2011) http://www.erasmusmc.nl/5663/135857/3664573/3397899/report-summary-investigation-integrity (21 October 2013).
3. Erasmus Medical College Press Release. (2011) http://www.erasmusmc.nl/corp-home/corp-news-center/2011/2011-11/ontslag.hoogleraar/?lang=en (21 October 2013).
4. Erasmus Medical Centre. (2012) http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity-report-2012-10.pdf?lang=en&lang=en (21 October 2013).
5. Dunkelgrun M, Boersma E, Schouten O, Koopman-Van Gemert A W M M, Van Poorten F, Bax JJ, Thomson IR, Poldermans D. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249:921-926.
6. Bouri S, Shun-Shin M, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomized controlled trials of beta-blockade to prevent perioperative death in noncardiac surgery. Heart 2014;100:456-464.
7. Poldermans D, Schouten O, Bax J, Winkel TA. Reducing cardiac risk in non-cardiac surgery: evidence from the DECREASE studies. Eur Heart J 2009;11:A9-14.
8. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-1847.
9. Poldermans D, Devereaux PJ. The experts debate: perioperative beta-blockade for noncardiac surgery-proven safe or not? Cleve Clin J Med 2009;76(Suppl. 4):S84-S92.
10. Swedberg K, Wedel H. 2-year survival with atenolol administration. Evid Based Cardiovasc Med 1998;2:33. discussion 33.
11. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996;335:1713-1720.
12. Poldermans D, Boersma E, Bax JJ, Thomson IR, Van De Ven L L M, Blankensteijn JD, Baars HF, Yo T, Trocino G, Vigna C, Roelandt J R T C, Van Urk H. for the DECREASE Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999;341:1789-1794.
13. Astra Zeneca LP. 2006. Toprol XL (metoprolol succinate) extended release tablets. Full prescribing information. http://tinyurl.com/Toprol-XL-starting-dose (2 September 2014).
14. Bouri S, Shun-Shin MJ, Cole GD, Francis DP. Preoperative Beta-blockade: Unanswered Questions Heart 2013. http://heart.bmj.com/content/early/2013/07/30/heartjnl-2013-304262/reply (30 January 2014).
15. Bartens W. (2014, March 3) Kunstfehlerskandal oder Panikmache? Süddeutsche. www.sueddeutsche.de (17 March 2014).
16. Sandberg A, Abrahamsson B, Regårdh CG, Wieselgren I, Bergstrand R. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990;30:S2-S16.
17. Sandberg A, Abrahamsson B, Svenheden A, Olofsson B, Bergstrand R. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a singleunit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res 1993;10:28-34.
18. http://www.pdr.net/drug-summary/metoprolol-tartrate?druglabelid=3114&id=1656#.
19. http://en.wikipedia.org/wiki/False-balance (15 May 2014).
20. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative β-blockade with mortalityand cardiovascular morbidity following major noncardiac surgery. JAMA 2013;309:1704-1713.
21. Sen S, Davies JE, Malik IS, Foale RA, Mikhail GW, Hadjiloizou N, Hughes A, Mayet J, Francis DP. Why does primary angioplasty not work in registries? Quantifying the susceptibilityofreal-world comparative effectiveness datatoallocation bias. Circ Cardiovasc Qual Outcomes 2012;5:759-766.
22. Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish Nationwide Cohort Study. JAMA Intern Med 2014;174:336-344.
23. European Society of Cardiology. http://www.escardio.org/about/press/press-releases/pr-13/Pages/joint-statement-perioperative-guidelines.aspx (30 January 2014).
24. Anekwe L. New guideline on β blockers challenges ESC advice. Lancet 2014;383:682.
25. Wilf-Miron R, Lewenhoff I, Benyamini Z, Aviram A. From aviation tomedicine: applying concepts of aviation safety to risk management in ambulatory care. Qual Saf Health Care 2003;12:35-39.
26. Wilmshurst P. Dishonesty in medical research. Med Leg J 2007;75:3-12.
27. Twelve month follow-up of improvement of human infarcted heart muscle by intracoronary autologous mononuclear bone marrow cells in chronic coronary artery disease after myocardial infarction. Controlled study with Intracoronary Autologous Mononuclear Bone Marrow Cell Transplantation (IACT-Study). Köstering M, Bartsch T, Zeus T, Brehm M, Schannwell CM, Strauer BE. Presentation at ESC Congress 2008. http://spo.escardio.org/eslides/view.aspx?eevtid=24&id=4522.
28. Shun-Shin MJ, Francis DP. Why even more clinical research studies may be false: effect of asymmetrical handling of clinically unexpected values. PLoS One 2013;8:e65323.
29. Francis DP, Mielewczik M, Zargaran D, Cole GD. Autologous bone marrowstem cell therapy in heart disease: silent discrepancies and scientific and editorial responses. Int J Cardiol 2013;168:3381-3403.
30. Strauer B-E, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010;12:721-729.
31. Strauer BE, Yousef M, Schannwell MC. The BEST-Heart-Study: the acute and long term benefit of autologous stem cell transplantation in 289 patients with chronic heart failure. In: Strauer, Ott, Schannwell, editors. Chapter 7 in "AdulteStammzellen". Dusseldorf: Dusseldorf University Press, 2009 ISBN 978-3-940671-13-4.
32. Fraccarollo D, Galuppo P, Bauersachs J. Novel therapeutic approaches to postinfarction remodelling. Cardiovasc Res 2012;94:293-303.
33. Strauer B-E, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. J Am Coll Cardiol 2011;58:1095-1104.
34. Lüscher TF. The bumpy road to evidence: why many research findings are lost in translation. Eur Heart J 2013;34:3329-3335.
35. Ioannidis J P A. Why most published research findings are false. PLoS Med 2005;2:e124.
36. Giannoni A, Baruah R, Leong T, Rehman MB, Pastormerlo LE, Garrell FE, Coats AJ, Francis DP. Optimal prognostic thresholds for peak oxygen consumption, ejection fraction and BNP in heart failure: do they exist? Systematic review and analysis of origin of apparent thresholds. PLOS One 2014;9:e81699. doi:10.1371/journal.-pone.0081699.
37. Nijjer SS, Pabari PA, Stegemann B, Palmieri V, Leyva F, Linde C, Freemantle N, Davies JE, Hughes AD, Francis DP. The limit ofplausibility for predictors ofresponse: application to biventricular pacing. JACC Cardiovasc Imaging 2012;5:1046-1065.
38. Shun-Shin M, Francis DP. Why are some studies of cardiovascular markers unreliable? The role of measurement variability and what an aspiring clinician scientist can do before it is too late. Prog Cardiovasc Dis 2012;55:14-24.
39. Francis DP. How easily can omissionof patients, orselection amongst poorly-reproducible measurements, create artificial correlations? Methods for detection and implications for observational research design in cardiology. Int J Cardiol 2013;167:102-113.
40. Shun-Shin MJ, Howard JP, Francis DP. Removing the hype from hypertension. BMJ 2014;348:g1937.
41. Feringa HH, Elhendy A, Bax JJ, Boersma E, De Jonge R, Schouten O, Karagiannis SE, Schinkel AF, Lindemans J, Poldermans D. Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography. Coronary Artery Disease 2006;17:255-259.
42. Feringa HH, Bax JJ, Elhendy A, De Jonge R, Lindemans J, Schouten O, Van Den Meiracker AH, Boersma E, Schinkel AF, Kertai MD, Van Sambeek MR, Poldermans D. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol 2006;98:111-115.
43. Paul K (2009) The Return of Depression Economics and the Crisis of 2008. W. W. Norton Company Limited. ISBN 978-0-393-07101-6.
44. Leiden University Investigation. (April 2 2012). http://medischcontact. artsennet.nl/artikel/113236/lumc-niet-betrokken-bij-fraude-poldermans.htm (17 March 2014).
45. Stephen M, Meirion J, Robert B (23 April 2013) "The 'magic' bomb detector that endangered lives all over the world". The Guardian.
46. http://news.bbc.co.uk/1/hi/world/middle-east/8477601.stm (19 October 2013).
47. http://www.judiciary.gov.uk/Resources/JCO/Documents/Judgments/r-vmccormack-sentencing-remarks-20130502.pdf (17 March 2014).
48. http://www.theguardian.com/politics/2014/jan/26/fraudster-paid-governmentpromote-fake-bomb-detectors (17 March 2014).
49. http://news.bbc.co.uk/1/hi/programmes/newsnight/8520303.stm (18 March 2014).
50. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J III, Gras D, Krum H, Sogaard P, Holzmeister J. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013;369:1395-1405.
51. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" careinsecondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-228.
52. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-734.
53. Strippoli G F M, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-651.
54. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. (GREACE Study Collaborative Group). Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-1922.
55. Terzic A, Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J 2014;35:1231-1234.
56. http://online.wsj.com/article/PR-CO-20130411-903583.html (14 May 2014).
57. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013;61:2329-2338.
58. http://www.c3bs.com/sites/default/files/financial-presentations/c3bsprospectus-en.pdf (15 May 2014).
59. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Online Appendix to Reply regarding The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). http://www.sciencedirect.com/science/article/pii/S0735109713053461#MMCvFirst (30 January 2014).
60. Mielewczik M, Cole GD, Nowbar AN, Schilling R, Whinnett ZI, Bordachar P, Wilmshurst P, Chambers JC, Olshanksy B, Morgan J, Israel C, Sethi AS, Van Houwelingen M, Cleland JG, Schmidt G, Francis DP. The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy inheart failURE). J Am CollCardiol 2013;62:2453.
61. Dingell JD. Shattuck Lecture-misconduct in medical research. N Engl J Med 1993;328:1610-1615.
62. http://www.escardio.org/about/press/press-releases/pr-11/Pages/Dismissal-Don-Poldermans.aspx (14 October 2013).
63. http://www.forbes.com/sites/larryhusten/2014/01/15/medicine-or-massmurder-guideline-based-on-discredited-research-may-have-caused-800000-deaths-in-europe-over-the-last-5-years/(17 March 2014).
64. Jones S, Shun-Shin MJ, Cole GD, Sau A, March K, Williams S, Kyriacou A, Hughes AD, Mayet J, Frenneaux M, Manisty CH, Whinnett ZI, Francis DP. Applicability of the iterative technique for cardiac resynchronization therapy optimization: fulldisclosure, 50-sequential-patient datasetoftransmitral Dopplertraces, with implications for future research design and guidelines. Europace 2014;16:541-550.
65. Sagan, Carl (writer/host) (December 14, 1980). "Encyclopaedia Galactica". Cosmos: A Personal Voyage. Episode 12. 01:24 minutes in. PBS.
66. Maddox J, Randi J, Stewart WW. "High-dilution" experiments a delusion. Nature 1988;334:287-291.
67. Piepoli MF, Vallisa D, Arbasi C, Cavanna L, Cerri L, Mori M, Passerini F, Tommasi, Rossi A, Capucci A. on behalf of the Cardiac Study Group. 2-Year follow-up results of the CARDIAC (CARDIomyoplasty by Autologous intraCoronary bone marrow in acute myocardial infarction) randomised controlled trial. Int J Cardiol 2013;168:e132.
68. http://www.forbes.com/sites/larryhusten/2014/01/15/medicine-or-massmurder-guideline-based-on-discredited-research-may-have-caused-800000-deaths-in-europe-over-the-last-5-years/(18 March 2014).
69. Regina v. Sleep, (1861) 169 Eng. Rep. 1296 (Cr. Cas. Res.).
70. Leon Festinger. Cognitive dissonance. Sci Am 1962;207:93-106. doi:10.1038/scientificamerican1062-93.
71. Chopra V, Eagle KA. The reply. Am J Med 2013;126:e7.
72. Poldermans D. Scientific fraud or a rush to judgment? Am J Med 2013;126:e5-e6.
73. Schouten O, Poldermans D, Visser L, Kertai MD, Klein J, Van Urk H, Simoons ML, Van De Ven LL, Vermeulen M, Bax JJ, Lameris TW, Boersma E. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J 2004;148:1047-1052.
74. http://retractionwatch.com/2014/01/20/quickest-withdrawal-ever-journalyanks-paper-alleging-800k-deaths-from-poldermans-affair/(18 March 2014).
75. Rogers L. (2014, January 26). 800, 000 'killed' by beta-blockers. The Sunday Times. Retrieved from www.thesundaytimes.co.uk (17 March 2014).
76. Cole GD, Francis DP. Research failure can result in lost lives. (Now Retracted) Eur Heart J 2014;35:135-137.
77. Lüscher TF, Gersh B, Landmesser U, Ruschitzka F. Is the panic about beta-blockers in perioperative care justified? Eur Heart J 2014;35:2438-2440.
78. European Society of Cardiology. 2014. Beta Blockers and Perioperative Care: European Heart Journal Editorial addresses controversy. http://www.escardio.org/about/press/press-releases/pr-14/Pages/Beta-Blockers-Perioperative-Care-EHJ-Editorial-addresses-controversy.aspx (17 March 2014).
79. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report. Heart 2013;99:1579-1578.
80. Howard JP, Cole GD, Sievert H, Bhatt DL, Papademetriou V, Kandzari DE, Davies JE, Francis DP. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions. Int J Cardiol 2014;172:29-35.
81. http://www.medpagetoday.com/Cardiology/Hypertension/43726 (18 March 2014).
82. Medtronic. 2014. Medtronic announced U. S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1889335&highlight= (17 March 2014).
83. Cole G, Francis DP. Comparable or STAR-heartlingly different left ventricular ejection fraction at baseline? Eur J Heart Fail 2011;13:234.
84. European Society of Cardiology (2010). STAR Heart Study maintained in ESC Congress 2010 Scientific Programme. http://www.escardio.org/about/press/press-releases/esc10-stockholm/Pages/strauer-star-study-maintained.aspx (17 March 2014).
85. Abbot A (2014, February 24) Evidence of misconduct found against cardiologist. Nature News Blog. Retrieved from: http://blogs.nature.com/news/2014/02/evidence-of-misconduct-cardiologist.html (17 March 2014).
86. Lüscher TF. The codex of science: honesty, precision, and truth- and its violations. Eur Heart J 2013;34:1018-1023.